Abstract
The classification criteria for axillary spondyloarthritis (axSpA) introduced in 2009 by the ASAS (Assessment of SpondyloArthritis International Society) reflect the complexity of the SpA symptoms. They are not only concerned with musculoskeletal disorders, but also with diseases associated with SpA, such as manifestations in the eye (uveitis), intestine (Crohn's disease or ulcerative colitis) or skin (psoriasis).
These criteria entail many responses and options, including a more timely detection of patients and the introduction of effective treatment. At present, we have methods of both highly effective pharmacological treatment using effective biological preparations - tumor necrosis factor-a inhibitors and interleukin 17 and non-pharmacological with the education of proper lifestyle and rehabilitation.
On the other hand, the application of these classification criteria in daily rheumatological practice carries difficulties with it such as the false positivity of the findings. In this paper, we will focus on both the two types of axial SpA - nonradiographic form (nr-axSpA) and the radiographic form (r-axSpA) which is known as ankylosing spondylitis.